# US 2015/0105332 A1 · Somatostatin receptor agonist formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105332 A1
- Document ID: US20150105332A1
- Status: Published application
- Kind: A1
- Application number: 14/401,559
- Filed: 2013-05-24
- Published: 2015-04-16
- Earliest claimed: 2012-05-25
- Assignees: Camurus AB
- Applicants: Camurus AB
- Inventors: Catalin Nistor; Markus Johnsson; Fredrik Tiberg
- Web page: https://patentgrep.com/patent/US20150105332A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1274: Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/31: Somatostatins
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

## Claims

### Claim 1

A pre-formulation comprising a low viscosity mixture of:
a) 20-50 wt. % of at least one diacyl glycerol;
b) 20-54 wt. % of at least one phosphatidyl choline (PC);
c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) 1 to 20 wt. % polar solvent
e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.

### Claim 2 (depends on 1)

A pre-formulation as claimed in claim 1 wherein the peptide somatostatin receptor agonist comprises or consists of pasireotide or a salt thereof.

### Claim 3 (depends on 1)

The pre-formulation as claimed in claim 1, wherein the peptide somatostatin receptor agonist consists of pasireotide and optionally octreotide.

### Claim 4 (depends on 1)

A pre-formulation as claimed in claim 1 wherein said pre-formulation comprises a peptide somatostatin receptor agonist dosage in the range of 10 to 100 mg/ml.

### Claim 5 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component a) comprises or consists of glycerol dioleate (GDO).

### Claim 6 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component b) comprises or consists of soy PC or PC with at least 95% PC head groups and at least 95% C16 to C20 acyl chains having 0 to 3 unsaturations.

### Claim 7 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component c) comprises or consists of ethanol, propanol, isopropanol or mixtures thereof.

### Claim 8 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component d) comprises water or propylene glycol or mixtures thereof.

### Claim 9 (depends on 1)

A pre-formulation as claimed in claim 1 wherein the antioxidant is ascorbic acid, ascorbyl palmitate, EDTA or citric acid.

### Claim 10 (depends on 1)

A pre-formulation as claimed in claim 1 wherein the antioxidant is excluded, in particular wherein ascorbic acid, EDTA and/or citric acid are excluded.

### Claim 11 (depends on 10)

A pre-formulation as claimed in claim 10 wherein component b) comprises or consists of DOPC; DPPC, DSPC; MPPC; MSPC; PMPC; POPC; PSPC; SMPC; SOPC; SPPC and mixtures thereof.

### Claim 12 (depends on 1)

A pre-formulation as claimed in claim 1 wherein said pre-formulation excludes fragmentation agents.

### Claim 13 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component a) is present at a level of 30-40% by weight.

### Claim 14 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component b) is present at a level of 30-45% by weight.

### Claim 15 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component c) is present at a level of 5-12 wt. %.

### Claim 16 (depends on 1)

A pre-formulation as claimed in claim 1 wherein component d) is present at a level of 1.2 to 20% by weight.

### Claim 17 (depends on 1)

A pre-formulation as claimed in claim 1 wherein components c) and d) combined are present at a total level less than or equal to 30% by weight.

### Claim 18 (depends on 1)

A pre-formulation as claimed in claim 1 wherein the ratio of components a:b is in the range 45:55 to 54:46.

### Claim 19 (depends on 1)

A pre-formulation as claimed in claim 1 wherein d) is water or aqueous fluid and the ratio of components c:d is in the range 40:60 to 70:30.

### Claim 20 (depends on 1)

A pre-formulation as claimed in claim 1 wherein d) is PG and the ratio of components c:d is in the range 90:10 to 25:75.

### Claim 21 (depends on 1)

A pre-formulation as claimed in claim 1 wherein said pre-formulation has an L2 phase structure.

### Claim 22 (depends on 1)

A pre-formulation as claimed in claim 1 comprising at least one formulation selected from those listed in Tables 1-3.

### Claim 23 (depends on 1)

A pre-formulation as claimed in claim 1 wherein GLP-1, GLP-1 analogues and GLP-1 receptor agonists and/or antagonists are not present.

### Claim 24 (depends on 1)

A pre-filled administration device containing a pre-formulation as claimed in claim 1.

### Claim 25 (depends on 24)

The device as claimed in claim 24 being a syringe or syringe barrel, a needle-less injector, a multi- or single-use injector, a cartridge or a vial.

### Claim 26 (depends on 24)

The device of claim 24 containing a single dose of 1 to 200 mg of peptide somatostatin receptor agonist.

### Claim 27 (depends on 24)

The device of claim 24 containing peptide somatostatin receptor agonist at around 0.2 to 4 mg per day between scheduled administrations.

### Claim 28 (depends on 24)

The device of claim 24 containing a total volume for administration of no more than 5 ml.

### Claim 29 (depends on 24)

A kit comprising an administration device as claimed in claim 24.

### Claim 30

A process for the formation of a pre-formulation suitable for the administration of a peptide somatostatin receptor agonist to a subject, said process comprising forming a low viscosity mixture of:
a) 20-50 wt. % of at least one diacyl glycerol;
b) 20-54 wt. % of at least one phosphatidyl choline (PC);
c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) 1 to 20 wt. % polar solvent
e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
and dissolving or dispersing at least one peptide somatostatin receptor agonist in the low viscosity mixture, or in at least one of components a), b), c), d) and optionally f) prior to forming the low viscosity mixture.

### Claim 31 (depends on 30)

The process as defined in claim 30 wherein the peptide somatostatin receptor agonist comprises or consists of pasireotide or a salt thereof.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1)

A method for the treatment of a human or non-human mammalian subject comprising administering to said subject a pre-formulation as claimed in claim 1.

### Claim 35 (depends on 34)

The method of claim 34 for the treatment of a human or non-human mammalian subject in need thereof, wherein said subject has Cushing's disease, acromegaly, type I or type II diabetes mellitus, and/or complications thereof, irritable bowel syndrome, inflammatory diseases, inflammatory bowel disease, psoriasis or rheumatoid arthritis, polycystic kidney disease, dumping syndrome, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis and gastrointestinal hormone secreting tumors, lymphocyte malignancies or gastrointestinal bleeding.

### Claim 36 (depends on 34)

The method of claim 34 for the treatment of a human or non-human mammalian subject in need thereof, wherein said subject has Cushing's disease or acromegaly.

### Claim 37 (depends on 34)

The method of claim 34 comprising administration by:
i) i.m. injection
ii) s.c. injection
iii) deep s.c. injection
iv) intravitreal
v) other parenteral administration routes.

### Claim 38 (depends on 34)

The method of claim 34 comprising administration by means of a pre-filled administration device.

### Claim 39 (depends on 34)

The method of claim 34 comprising a single administration every 20 to 100 days.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)
